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Abstract
For all diseases, prevalence has been carefully studied. In the “classic” paradigm, the preva-
lence of different diseases has usually been studied separately. Accumulating evidences have
shown that diseases can be “correlated”. The joint analysis of prevalence of multiple diseases
can provide important insights beyond individual-disease analysis, however, has not been well
conducted. In this study, we take advantage of the uniquely valuable Taiwan National Health In-
surance Research Database (NHIRD), and conduct a pan-disease analysis of period prevalence
trend. The goal is to identify clusters within which diseases share similar period prevalence
trends. For this purpose, a novel penalization pursuit approach is developed, which has an
intuitive formulation and satisfactory properties. In data analysis, the period prevalence values
are computed using records on close to 1 million subjects and 14 years of observation. For
405 diseases, 35 nontrivial clusters (with sizes larger than one) and 27 trivial clusters (with
sizes one) are identified. The results differ significantly from those of the alternatives. A closer
examination suggests that the clustering results have sound interpretations. This study is the
first to conduct a pan-disease clustering analysis of prevalence trend using the uniquely valuable
NHIRD data and can have important value in multiple aspects.
Keywords: Disease prevalence; Temporal trends; Clustering; NHIRD.
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1 Introduction
For most if not all diseases, prevalence, both its specific values and temporal and spatial trends, have
been well examined. The analysis of disease prevalence has important implications for the allocation
and planning of medical resources, identification of risk factors, development of interventions, and
other purposes. Accordingly, statistical methods have been extensively developed for analyzing
disease prevalence, ranging from simple summary statistics to advanced nonparametric fitting. We
refer to the literature for detailed discussions on clinical interpretation and application (Rothman,
2012) and statistical methodology (Keiding, 1991).
Under the “classic” paradigm, prevalence, as well as other outcomes, have been studied for
each disease separately. Accumulating evidences have shown that diseases can be “correlated”.
Examples include the positive correlations in the occurrence, prognosis, and other outcomes of
breast cancer and ovarian cancer, which are attributable to the shared molecular risk factors and
hormone-related treatment regimens. Another example is the positive correlations in the occurrence
and other outcomes of asthma, lung cancer, and other respiratory diseases, which are attributable
to the shared environmental and genetic risk factors. Recent studies have shown that the joint
analysis of multiple diseases can lead to important insights not shared by its individual-disease-
based counterpart (Rzhetsky et al., 2007; Goh et al., 2007).
For prevalence, the outcome of interest in this study, the joint analysis of multiple diseases has
been conducted. For example, a prospective observational study conducted in the U.S. focuses
on the prevalence of chest pain and acute myocardial infarction (MI) and suggests that patients
without chest pain on presentation represent a large segment of the MI population and are at an
increased risk for delays in seeking medical attention (Canto et al., 2000). Another example is
the cancer metastasis networks, which have been established based on clinical data (Chen et al.,
2009). Despite several interesting findings, our literature review suggests that the existing joint
analyses of prevalence have the following limitations. Some studies focus on a small number of pre-
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selected diseases (for example, heart diseases only) and do not have a “global” perspective. The
interconnections in prevalence among diseases are still largely unknown, and it is desirable to con-
duct “unguided learning” and identify new interconnections. Some studies conduct cross-sectional
analysis. It has been recognized that temporal and spatial variations can have more important
implications than static values. There are also studies with limitations in quantitative analysis by
adopting (overly) simple statistical methods. In the single-disease analysis of prevalence (and other
outcomes), it has been shown that sophisticated statistical methods, for example nonparametric
modeling, have the power to produce important findings missed by simple statistics. Some other
studies are based on limited data, for example, collected from a small number of hospitals and
communities. Such data, although interesting to a certain extent, have a selection bias problem
and cannot describe the more valuable population-level properties.
Figure 1: Prevalence trends for ten diseases. Left: original measurements. Right: their clustering.
Our ultimate goal is to understand disease interconnections in terms of prevalence temporal
trend. In this article, the specific goal is to identify clusters, within which diseases share similar
prevalence temporal trends. To fix ideas, a symbolic presentation of our motivation and the pro-
posed analysis is provided in Figure 1. In the left panel, we show the temporal trends of period
prevalence for ten diseases, which may seem unstructured. However, if we ignore the absolute val-
ues and move the prevalence curves vertically, as shown in the right panel, the ten diseases clearly
form three clusters, with those in the same cluster having similar trends.
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In the literature, much attention has been paid to the magnitude of prevalence. In contrast,
research on the shared temporal trends of diseases’ prevalence has been extremely rare. However,
it can have important implications beyond that on absolute magnitude. Specifically, the absolute
magnitude of a disease’ prevalence can be largely attributable to time-independent risk factors,
such as genetic predisposition. In contrast, the variation of prevalence over time can be mostly
attributable to time-varying factors, such as weather conditions, air/water quality, development
of prevention programs, and others. If two diseases share similar temporal trends of prevalence,
no matter their absolute magnitudes are close or not, it is sensible to conjecture that they share
time-dependent risk factors and/or are affected by similar prevention programs. Such risk factors
and prevention programs are more actionable than, for example, genetic predisposition. As such,
the proposed analysis of shared temporal trends may have important practical implications not
possessed by that on absolute magnitude.
This study can contribute beyond the existing literature in the following aspects. The proposed
study objective, identification of diseases with shared prevalence trends via clustering analysis,
innovatively differs from those in the existing studies, which usually focus on the static, absolute
magnitudes. A large number of diseases are simultaneously analyzed. Avoiding pre-selection can
lead to discoveries beyond existing knowledge. The pan-disease analysis can facilitate a more
“global” description of disease prevalence. The analyzed NHIRD data is uniquely valuable with
a huge sample size and virtually no selection bias, which can lead to more credible and unbiased
findings. In addition, a novel analysis method is implemented, which has a sound statistical basis
and numerically outperforms multiple existing alternatives. It can have broad applications far
beyond this study and thus independent value. Overall, this study may have significant biomedical
as well as statistical merits.
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2 The National Health Insurance Research Database (NHIRD)
Taiwan launched the single-payer National Health Insurance (NHI) program on March 1st, 1995.
As of 2014, 99.9% of Taiwan’s population were enrolled. With the high cost of healthcare that
is uninsured or covered by commercial insurance, almost all hospital/clinic-based healthcare has
been going through NHI. Under NHI, hospitals and clinics are obligated to report detailed diagnosis
(and treatment) data. Such data have been collected under the National Health Insurance Research
Database (NHIRD) project (http://nhird.nhri.org.tw/en/). The NHI data have unique advantages,
especially including unbiasedness (virtually the whole population is covered), comprehensiveness
(information is available on all diagnosis/treatment episodes), and unity (all data collection follows
the same protocol), and have served as the basis of a large number of epidemiological, clinical,
health economic, and management studies (close to 400 publications on pubmed).
The proposed analysis may not be feasible with other databases. Specifically, hospital and
community-based databases suffer from small sample sizes and a potential selection bias; Databases
such as Medicare and Medicaid do not cover the general population and hence also have a selection
bias problem; And those based on specific commercial insurance schemes are very difficult to access
and suffer from a similar selection bias problem.
There are multiple ways of defining prevalence. In this study, we focus on period prevalence,
which is defined as the percentage of the population with a certain disease within a fixed period of
time (in our analysis, one year). The health care and insurance system in Taiwan is among the most
developed, and undertreatment (presence of illness conditions that are not treated), although may
exist, is expected to be rare. As such, the number of people treated with a certain disease (within
one year) can provide a reasonable approximation to the number of people with this disease.
The analyzed data are extracted from NHIRD and contain records on 1 million randomly
selected subjects (about 4.3% of the Taiwan population) for the period of 2000-2013. Disease di-
agnosis (and hence period prevalence) information is extracted from both outpatient and inpatient
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treatments, using the NHIRD CD (Ambulatory care expenditures by visits) and DD (Inpatient
expenditure by admissions) files. For disease definition, the ICD-9-CM code version 1992 (used
before 2005) is transformed into the 2001 version. Records with the ICD-9-CM codes E and V
(external causes of injury and supplemental classification), 630-679 (pregnancy, childbirth, and
puerperium complications), and 760-999 (symptoms, sins, and ill-defined conditions) are removed
from analysis following published literature. A small number of inconsistent records are removed.
The final analyzed dataset contains records on 986,650 patients, and the disease period prevalence
values are computed based on 173,355,725 outpatient and 1,381,749 inpatient treatment episodes.
With the large number of observations, the accuracy of analysis may far exceed many peer studies.
ICD-9-CM contains more than 14,000 diseases, and directly using this code leads to very few diag-
noses for many diseases. We apply the Phenome-Wide Association Study (PheWAS) vocabulary
approach (Wei et al., 2017) and group the 14,000 ICD-9-CM diseases into 1,723 disease codes.
It is realized that even with a huge sample size, the prevalence values for rare diseases may not
be reliably estimated. As such, we remove diseases with extremely low prevalence. To make the
analysis “more interesting”, we further focus on two types of diseases. The first type of diseases are
those with high prevalence and/or high mortality, for example upper respiratory tract infections,
disease of the circulatory system, cancers, and others. Such diseases have significant public health
implications. The second type of diseases are those with high clinical significance, for example,
those with no effective treatment or clear causes, such as some cancers (e.g., melanoma), some
diseases of the blood and blood-forming organs (e.g., autoimmune hemolytic anemias), congenital
coagulation defects, and others.
A total of 405 diseases are included in the final analysis. This number is considerably larger
than those in the existing studies. It is noted that the proposed analysis can be straightforwardly
extended to all diseases. However, as for each disease the number of prevalence measurements
(number of years) is rather limited, and as each disease is allowed to have its unique prevalence
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trend (details below), the analysis may become less reliable with a larger number of diseases.
Among the analyzed diseases, those with the highest prevalence include acute upper respiratory
infections of multiple or unspecified sites, dental caries, acute bronchitis and bronchiolitis, acute
sinusitis and others, all of which have been extensively studied in the literature. Those with the
highest temporal variations include acute upper respiratory infections of multiple or unspecified
sites, noninfectious gastroenteritis, gingivitis, essential hypertension, and others. Multiple different
types of trends are observed, including virtually flat (for example, Takayasu’s disease), increasing
(for example, uterine leiomyoma), decreasing (for example, ulcerative colitis (chronic)), “U” shape
(decreasing and then increasing; for example, benign neoplasm of thyroid glands), reversed U shape
(for example, other diseases of the teeth and supporting structures), and others. More details are
presented in Section 4 as well as available from the authors.
3 Methods
As can be partly seen from Figure 1, the proposed analysis basically poses a functional clustering
(classification) problem. In the literature, multiple approaches have been developed. Examples
include the functional K-means and those alike, which, under certain data/model assumptions,
compute the `2 distance between functions, and then conduct clustering in a similar way as for
scalars. There are also methods that are more model-based. They assume that the observed
functions (or their values at discrete time points) are generated from some underlying paramet-
ric/nonparametric functions, which are then recovered for the purpose of clustering. For relevant
discussions, we refer to Jacques & Preda (2014), Abraham et al.(2003), and Peng & Mu¨ller (2008).
3.1 A penalization pursuit approach
In “simple” clustering analysis with finite-dimensional random variables, it has been observed that
no clustering approach is dominatingly better. It is thus always of interest to develop alternative
methods. This can be especially true for functional clustering, considering the scarcity of avail-
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able methods. In addition, as to be described below, the proposed method has multiple unique
advantages.
In the analysis of NHIRD data, we have 14 period prevalence values (one per year) for each
of the 405 diseases. Generically, assume that for each disease, the observed prevalence values are
realizations of an unknown curve in L2[a, b], where [a, b] is a finite interval. Denote N as the number
of diseases (sample size), y1(·), ..., yN (·) as the N prevalence curves, and t1, ..., tT ∈ [a, b] as the T
time points of observation. As described above, the proposed analysis focuses on trend as opposed
to absolute magnitude. As such, prior to analysis, yi’s are normalized to have “means” zero, and
with a slight abuse of notations, we still use yi’s to denote the normalized values. Following a
popular strategy in functional analysis, we conduct basis expansion. Specifically, consider
yi(tj) ≈
K∑
l=1
βilφl(tj) + ij , ij
i.i.d∼ N(0, σi), i = 1, ..., N, j = 1, ..., T. (1)
Here {φl, l = 1, . . . ,K} is a set of K basis functions in L2[a, b], and βil’s are the unknown regression
coefficients. In the literature, extensive works are available on choosing the form and number of
basis functions and will not be reiterated here. Note that for the present problem, the assumption
of independent errors can be sensible.
Denote Yi = (yi(t1), . . . , yi(tT ))
′, B =
φ1(t1) . . . φK(t1)... . . . ...
φ1(tT ) . . . φK(tT )
, and βi = (βi1, ..., βiK)′. We
consider the estimate
{βˆj : j = 1, . . . , N} = argmin

N∑
i=1
1
2
‖Yi −Bβi‖2 + λ
∑
i<j
wij‖βi − βj‖
 , (2)
where λ > 0 is a data-dependent tuning parameter and wij ’s are data-dependent weights. In our
numerical study, we set wij = ‖βˆolsi − βˆolsj ‖−1 with βˆolsi = argmin‖Yi−Bβi‖2. Diseases i and j are
concluded as in the same cluster if βˆi = βˆj.
Rationale Here we adopt the popular basis expansion estimation approach. The proposed analysis
can generate functional clusters as well as estimated prevalence curves for these clusters as a
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“byproduct”, which may facilitate interpretation and other purposes. The proposed approach
innovatively “transforms” clustering into a penalized pursuit problem, and relies on penalization to
data-dependently determine the number of clusters, clustering structure, etc. This strategy allows
sufficient flexibility. For example, there is no assumption/constraint on the sizes of clusters, and it
is possible that a disease forms a cluster of its own. The strategy of clustering via penalization is
pioneered in recent studies (Shen & Huang , 2010). Significantly advancing from the literature, the
proposed analysis is conducted on a large number of functions in the disease prevalence analysis.
As each curve is represented by multiple basis functions and their regression coefficients, group
penalization is needed. Here the group Lasso is adopted and can be replaced by other group
penalties. An adaptive penalization is adopted to improve performance. There are extensive
discussions in the literature on group and adaptive penalization and will not be reiterated here.
In “classic” nonparametric estimation, penalty is usually imposed on βi’s. The present analysis
goal differs from that in the existing studies, and the differences βi − βj ’s are penalized to achieve
clustering. When desirable, additional penalties can be imposed on βi’s. In modeling, it is assumed
that σi’s may vary across diseases. It is possible to estimate σi’s from OLS and construct a
variance-weighted loss function. However, as a large number of variances need to be estimated, the
unweighted objective function may be more stable and performs well as long as the variances are
not too heterogeneous.
3.2 Computation
To simplify notation, consider the unweighted optimization
minβ
N∑
i=1
1
2
‖yi −Bβi‖2 + λ
∑
i<j
‖βi − βj‖.
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As in (7) the weights are predetermined, its optimization can be conducted in exactly the same
manner. The above optimization can be written as
minβ
N∑
i=1
1
2
‖yi −Bβi‖2 + λ
∑
i<j
‖zij‖, subject to βi − βj − zij = 0.
Let β = (β1, ..., βN )
′, z = (z12, ..., z(N−1)N )′, vij ∈ RK , v = (v12, ..., v(N−1)N )′. The augmented
Lagrangian is given by:
Lρ(β, z, v) =
n∑
i=1
1
2
‖yi −Bβi‖2 + λ
∑
i<j
‖zij‖+ ρv′ij(βi − βj − zij) +
ρ
2
‖βi − βj − zij‖22.
For optimization, we adopt the ADMM technique, which is iterative with the following updates at
iteration m+ 1:
β
(m+1)
i = argminβiLρ(β, z
(m), v(m)), i = 1, ..., N, (3)
z
(m+1)
ij = argminzijLρ(β
(m), z, v(m)), i < j, (4)
v
(m+1)
ij = v
(m)
ij + ρ
∑
i<j
(β
(m+1)
i − β(m+1)j − z(m+1)ij ). (5)
Taking derivative w.r.t βi, we obtain
dL
dβi
= −B′(yi −Bβi) + ρ
∑
i<j
vij − ρ
∑
i>j
vji + ρ
∑
i<j
(βi − βj − zij)− ρ
∑
i>j
(βj − βi − zji).
With this equation, we can have
β
(m+1)
i = (B
′B + (n− 1)ρ)−1
B′yi + ρ∑
i<j
v
(m)
ij − ρ
∑
i>j
v
(m)
ji + ρ
∑
i<j
z
(m)
ij −
∑
i>j
z
(m)
ji −
∑
i 6=j
β
(m)
j
 .
Taking derivative w.r.t zij and equating to 0 yield
z
(m+1)
ij =
(
‖b(m+1)i − b(m+1)j + v(m)ij ‖ −
λ
ρ
)
+
b
(m+1)
i − b(m+1)j + v(m)ij
‖b(m+1)i − b(m+1)j + v(m)ij ‖
.
Overall, with a fixed tuning parameter λ, the ADMM algorithm uses 0 or the OLS estimate as the
starting value and iterates as described above until the difference between two consecutive estimates
is small enough (such that convergence can be concluded).
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Tuning parameter selection λ controls the degree of shrinkage and hence the number of clusters
and clustering structure. In the extreme case with λ =∞, all diseases are clustered together; and
λ = 0 leads to one disease per cluster.
It is noted that, different from most of the existing functional studies, the curves are not all
iid realizations of the same underlying distribution. Potentially, a curve can be unique and form
its own cluster. As such, commonly used methods such as the standard V-fold cross validation are
not directly applicable. For each curve, we split the T observations into a training and a testing
set. The training set consists of the odd-numbered observations, and the testing set consists of the
rest. Denote βˆtraini ’s as the training set estimates. For curve i, denote Cˆ(i) as the estimated cluster
membership. Assume that the first Cˆ1 clusters are nontrivial with sizes larger than one, and the
rest Cˆ − Cˆ1 clusters have sizes one. Denote Y testi and Btest as the testing set counterparts of Yi
and B. We propose selecting λ that minimizes
N∑
i=1
‖Y testi −Btestβˆtraini ‖2 +
Cˆ1∑
c=1
∑
i,j:Cˆ(i)=Cˆ(j)=c
‖βˆtraini − βˆtrainj ‖+
Cˆ∑
c=Cˆ1+1
‖βˆtrain
j:Cˆ(j)=c
‖. (6)
This has been partly motivated by the split-half tuning parameter selection for time series and
other data, is expected to behave reasonably if the curves are relatively “stable”, and observed to
have satisfactory numerical performance. In practice, we conduct a grid search for the optimal λ.
3.3 Simulation
Simulation is conducted to gain insights into the practical performance of the proposed method.
In the first set of simulation, functions are generated as the cluster-specific mean functions plus
random errors. Observations are then made for each function at 20 equally spaced time points with
t1 = 0.1, . . . , t20 = 2. For all i and j, ij ∼ N(0, σ).
A total of eight clusters are defined as follows. Cluster 1 Let ψj(t), j = 1, 2 be the monomial
basis. yi(tj) = 2 − ψ1(tj) − 1.5ψ2(tj) + ij . Cluster 2 Let ψj(t), j = 1, 2 be the monomial basis.
y(tj) = ψ1(tj) + 1.5ψ2(tj) + ij . Cluster 3 y(tj) = I(tj ≤ 1)(1− |tj − 1|) + I(tj > 1) + ij . Cluster 4
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y(tj) = 2I(tj ≤ 1)(|1 − tj |) + ij . Cluster 5 Let ψj(t), j = 1, ...5 be the Fourier basis. y(tj) =
3 − 2ψ1(tj) − 0.8ψ2(tj) − ψ3(tj) − 1.1ψ4(tj) − 0.5ψ5(tj) + ij . Cluster 6 Let ψj(t), j = 1, ...5 be
the Fourier basis. y(tj) = 2ψ1(tj) + 0.8ψ2(tj) + ψ3(tj) + 1.1ψ4(tj) + 0.5ψ5(tj) + ij . Cluster 7
y(tj) = 2(1−|tj−1|)+ ij . Cluster 8 y(tj) = 2(1−|tj |)+ ij . To better comprehend the clusters, we
present the mean functions (solid lines) as well as randomly realizations (dashed lines) in Figure 2.
Figure 2: Simulation: mean functions (solid lines) and random realizations (dashed lines).
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For the sizes of clusters, we consider two scenarios: Scenario 1 has equal sizes with n1 =
. . . = n8 = 12, and Scenario 2 has unequal sizes with n1 = 11, n2 = 17, n3 = 15, n4 = 9, n5 =
11, n6 = 13, n7 = 14, n8 = 10. In addition, we also consider different random error levels with
σ = 0.1, 0.2, 0.3, 0.4. In our analysis, clustering is of the highest interest. To evaluate clustering
accuracy, consider the N × N matrix A, whose (i, j)th element is 1 if curves i and j belong to
the same cluster and 0 otherwise. Denote the estimate of A as Aˆ. We define clustering Error =∑
i<j |A(i, j)− Aˆ(i, j)|, which is the unnormalized error count.
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Table 1: Simulation I: mean clustering errors.
σ Proposed Alt.1 Alt.2 Alt.3 Alt.4 Alt.5 Alt.6
Scenario 1 0.1 0.0 300.3 92.2 5.7 1344.8 0.0, 146.7 865.3
0.2 0.0 328.0 1019.0 34.6 1199.1 63.8, 110.4 889.9
0.3 9.0 455.2 2151.8 125.1 1277.2 144.3, 154.4 656.7
0.4 298.8 544.0 2381.3 177.0 1344.0 157.0, 165.1 458.5
Scenario 2 0.1 0.5 259.0 121.4 3.4 1554.5 0.0, 125.2 580.1
0.2 0.4 391.5 1021.0 44.8 1316.5 141.4, 166.6 739.0
0.3 25.2 505.3 1958.3 145.0 1385.2 230.3, 227.7 567.6
0.4 426.0 579.4 2167.6 207.7 1407.0 231.2, 236.9 638.4
To better gauge performance of the proposed method, we also consider six relevant competitors.
[Alt.1] This method is proposed by Abraham et al. (2003). It first fits data using B-splines (for
each curve separately) and then conducts clustering of the estimated B-spline coefficients using the
K-means approach. [Alt.2] The OLS estimates are first obtained for each curve separately. Then
curves i and j are clustered together if ‖βˆOLSi − βˆOLSj ‖ < η. Here η serves as a tuning parameter
and controls the number and structure of clustering. For determining the optimal η, we adopt an
approach similar to that in Section 3.2. [Alt.3] This method is proposed by Bouveyron et al. (2015)
and based on mixture modeling. It takes functions as input. As such, we implement a smoothing
method to obtain functions passing through the observed discretized points (more details can be
found in Ramsay & Silverman (2005)). This method is implemented using the R package funFEM.
Specifically, we specify the range of the number of clusters to be from 2 to 10 and select the “all”
option, which allows for the implementation of all the 12 models proposed in this work and selects
the optimal one. [Alt.4] This is a curve clustering method using the functional random variable
density approximation and proposed in Jacques & Preda (2013). It is realized using the R package
Funclustering. We set the number of clusters as eight, which may lead to favorable performance.
[Alt.5] The FClust approach, which can be realized using the R package fdapace, conducts functional
clustering and identification of data substructures for longitudinal and other functional data. In
the original development, data-dependent determination of the number of clusters is not proposed.
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Here we consider two cases. The first is to set the number of clusters as the true. The second is to
consider the number of clusters as true+1, which may serve as a sensitivity analysis. [Alt.6] The
funHDDC method, which can be realized using the R package funHDDC, conducts model-based
clustering and identification of functional subspaces. It is originally developed for time series data.
For all seven methods, clustering errors are computed based on 100 replicates and presented in
Table 1.
The proposed approach is observed to have competitive performance. For example under simu-
lation Scenario 1 with σ = 0.3, it has mean clustering error 9.0, compared to 455.2 (Alt.1), 2151.8
(Alt.2), 125.1(Alt.3), 1277.2 (Alt.4), 144.3 and 154.4 (Alt.5, with the number of clusters equal to
true and true+1, respectively), and 656.7 (Alt.6). When the noise level increases, performance of all
methods deteriorate, as expected. When σ = 0.4 or higher, the proposed approach has reasonable
but less competitive performance. A closer examination suggests that, for this specific simulation
setting, this is largely caused by clusters 1 and 4. Figure 2 suggests that when the noise level is high
enough, the two clusters become virtually indistinguishable. Alt.3 and Alt.5 are observed to have
relatively “robust” performance when noise increases. It is noted that the simulated mean curves
have “nicer properties” (compared to what may be encountered in general), which may favor Alt.3
taking the functional curves as input. It is also noted that, for Alt.5 and other alternatives, the
favorable performance is attributable to the true number of clusters. Unlike the proposed, these
methods do not have an easy way of data-dependently determining the cluster number. If the
number of clusters is off, their performance may deteriorate significantly.
The second simulation is built on the first one. Here we set σ = 0.3 and consider: Scenario
3 with n2 = 25, n4 = 25, n5 = 5, n7 = 25, and n1 = n3 = n6 = n8 = 0, and Scenario 4 with
n1 = 25, n3 = 5, n6 = 25, n8 = 25, and n2 = n4 = n5 = n7 = 0. Here there are four clusters, and
the cluster sizes are highly unbalanced. Here we also examine performance of the proposed and
alternative methods as T , the number of observation points, increases.
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Table 2: Simulation II: mean clustering errors.
T Proposed Alt.1 Alt.2 Alt.3 Alt.4 Alt.5 Alt.6
Scenario 3 20 50.8 779.6 1361.7 572.7 911.6 0.0, 83.4 101.5
40 0.1 198.3 981.4 578.3 980.0 0.0, 77.3 733.1
200 0.0 248.2 36.8 575.0 581.2 0.0, 80.8 496.0
Scenario 4 20 3.8 309.3 513.0 522.8 590.4 0.0, 88.7 186.9
40 0.5 224.4 27.6 575.2 622.3 0.0, 78.8 592.5
200 0.0 316.6 0.4 584.8 502.3 0.0, 77.4 508.8
Table 2 suggests that as T increases, performance of the proposed method improves fast and
significantly. When T = 40 or larger, the proposed approach virtually has no clustering error.
Performance of Alt.2 also improves. This is reasonable, as loosely speaking, it shares a similar
spirit as the proposed: both of them can be viewed as a certain form of thresholding. Performance
of the other alternatives may be “less sensitive” to T . A “counterintuitive” observation is that
performance of some alternatives may get slightly worse when T is large, which can be caused by
the overly wiggly estimated functions. It is also observed that with Alt.5, if the number of clusters
is set as true, performance can be extremely well. However, it becomes less satisfactory when the
number of clusters is off.
4 Analysis of NHIRD data
Data described in Section 2 are analyzed using the proposed approach. A total of 35 nontrivial
clusters (with sizes larger than one) are identified. In addition, there are also 27 diseases forming
their own individual clusters. For the identified clusters, we plot the observed period prevalence
curves (without normalization) in Figure 2. Here different colors are used to represent different
prevalence levels. The detailed disease information is provided in Appendix II.
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Figure 3: Data analysis: clustering results using the proposed approach
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A total of 201 diseases in the first 14 clusters in general have increasing trends. However, the
shapes show considerable differences. As discussed in the literature, disease prevalence is affected
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by both genetic and non-genetic factors. With most if not all investigated diseases being genetically
highly stable, the observed variations in prevalence are mostly attributable to non-genetic factors.
For example, environmental factors, which usually vary over time, have been suggested as causal
for the increase in prevalence of certain diseases. Factors identified in the literature include worse
air quality, unhealthier dietary behaviors, stressful working conditions, and others. In addition,
the development of more effective diagnostic tools may also contribute to the observed increasing
prevalence (Abdollah et al., 2013). A closer examination of Table 4 suggests that the clustering
results may have sensible biomedical interpretations, with evidences reported in the literature
observed worldwide as well as in Taiwan. Consider as an example cancers, which have important
medical and public health implications and have been observed to have increasing trends. In
Netherlands, Brazil, Iran, as well as many other countries, population-based studies have reported
an increasing prevalence of melanoma. More related to the Taiwan population, a study conducted
in mainland China analyzed the National Central Cancer Registry Database for the period of 1998
to 2007 and reported an increase in the prevalence of colorectal cancer. It is suggested that the
increasing trend will continue in the near future (Dai et al., 2012). The analysis of Taiwan Cancer
Registry data, a database independent of NHIRD, suggests that oral cancer (OC) is one of the
fastest growing malignancies in Taiwan, which is largely attributable to certain unhealthy lifestyle
factors, including tobacco smoking, alcohol drinking, and betel quids chewing (Chiang et al., 2010).
Also included in clusters 1-14 and showing increasing prevalence include diseases such as Alzheimer’s
disease, hypertensive heart disease, chronic kidney disease, HIV infection, and others. They all have
been observed to have increasing prevalence in the literature. The main goal of the proposed analysis
is to identify clusters of diseases, which may be caused by shared risk factors. Examining clusters
1-14 suggests that there are sound interpretations for certain diseases being clustered together. For
example, cluster 9 includes human papillomavirus (HPV) associated malignant neoplasm of uterus,
cancer of tongue/nasopharynx, acute/prostatitis as well as orchitis and epididymitis. They share
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the same risk factor HPV (Bonneau et al., 2014). In cluster 11, hyperglyceridemia and disorder
of lipoid metabolism are confirmed risk factors of myocardial infarction and hypertension (Austin
et al., 1998). The latter can lead to myocardial infarction, hypertensive chronic kidney disease,
and cerebrovascular disease (Kario et al., 2004). In addition, acute renal failure is another risk
factor of chronic kidney disease (Lo et al., 2009). As core symptoms of depression (Nutt et al.,
2008), sleep disorders, depression, and major depressive disorder are grouped together (cluster 12).
Our clustering analysis also identifies diseases sharing similar prevalence trends but do not yet
have solid support from the literature. For example, acquired coagulation factor deficiency and
renal osteodystrophy have very similar prevalence trends, but there is a lack of evidence for their
connections. This can be caused by chance, connections with other diseases that are connected, as
well as unidentified shared risk factors. More exploration is needed in the future.
In the next 7 clusters (15-21), a total of 55 diseases showing various decreasing prevalence trends.
The decrease in disease prevalence can be caused by prevention interventions (lowering incidence),
improvements in treatment and care, as well as disease-modifying interventions (preventing or slow-
ing progression). Many of the decreasing trends observed in Figure 2 have also been reported in the
literature for Taiwan as well as other countries/regions, and plausible causes have been suggested.
For example, a decreasing trend of tuberculosis (TB) has been reported in most countries over
the past decade, which is largely attributable to national tuberculosis control programs (Ohmori
et al., 2002). As above, many of the observed co-clusterings of diseases also have sound interpreta-
tions. For example, CNS infection/poliomyelitis and encephalitis are both included in cluster 15.
CNS infection is a major risk factor of encephalitis (Annegers et al., 1988). In cluster 18, acute
rheumatic heart disease often leads to heart valve disorders and can cause ischemic heart disease
as well as acute pulmonary heart disease when the condition deteriorates (Young et al., 2006). As
for the increasing trends, there are also new discoveries that warrant additional investigation. For
example, cysts of oral soft tissues and duodenal ulcer have very similar trends in cluster 20. Their
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interconnection, if exists, has not been well established in the literature.
Diseases in cluster 22-30 have relatively flat prevalence with small fluctuations. Such diseases
may be not heavily influenced by varying environmental risk factors, or the relevant environmental
risk factors are rather “constant” over time, or the absolute values of prevalence are too low.
Examples include obesity, umbilical hernia, congenital coagulation defects, and Takayasu’s disease.
A total of 12 diseases with “irregular” trends are included in cluster 31-35. The “irregularity”
in prevalence can be caused by the development of intervention programs, outbreaks of chronic
diseases, and other factors. A close examination suggests that the observed irregular trends also
have sound interpretations. Consider for example varicella infection. It has the highest age-specific
incidence in children aged <9 years. Overall, the prevalence of varicella shows a decreasing trend.
More specifically, it fluctuates in the period of 2000 to 2004, and then decreases steadily from
2005 to 2013. The varicella vaccine was introduced in Taiwan in July 1997. Taipei City included
the varicella vaccine in its free pediatric vaccination program for children aged >12 months in
1998. Taichung City/County followed this protocol in 1999. However, the varicella vaccination
was not included as a part of routine immunization in all practices of child care until 2004 (Chao
et al., 2012). As such, fluctuations are observed for the 2000-2004 period; and a steady decrease
is observed starting 2005. For the irregular trends, the interconnections among diseases can be
more specific to Taiwan, and both intervention programs and disease outbreaks are highly disease
specific.
There are also 27 diseases that form their own individual clusters. Most of them are common up-
per respiratory tract infections and oral diseases. The top eight with the highest prevalence include
acute upper respiratory infections, acute bronchitis and bronchiolitis, acute sinusitis, gingivitis,
periodontitis (acute or chronic), essential hypertension, noninfectious gastroenteritis, and acute
pharyngitis, all with prevalence higher than 10 cases per 100 persons. The high prevalence values
easily lead to high variations. As such, although some of these diseases may seem to have similar
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trends as those previously clustered, they do not belong to the same clusters. Examples include the
acute upper respiratory infections (which is not clustered) and duodenal ulcer (cluster 20), both
of which have seemingly similar decreasing trends but have different levels of variations and hence
are not clustered together. Another example is gingivitis (un-clustered) and hypercholesterolemia
(cluster 13).
Table 3: Data analysis: discrepancy in clustering between different methods
Proposed Alt.1 Alt.2 Alt.3 Alt.4 Alt.5 Alt.6
Alt.1 0.17 0
Alt.2 0.14 0.22 0
Alt.3 0.82 0.69 0.75 0
Alt.4 0.78 0.66 0.72 0.17 0
Alt.5 0.13 0.19 0.19 0.72 0.68 0
Alt.6 0.90 0.77 0.81 0.07 0.19 0.79 0
Clustering is also conducted using the six alternative approaches described in simulation. The
resulted numbers of clusters are 20 (Alt.1), 19 (Alt.2), 10 (Alt.3), 12 (Alt.4), 10 (Alt.5), and 2
(Alt.6). The counterparts of Figure 3 for the alternatives are presented in Figures 4-9 in Appendix
III. More detailed information on the clustered diseases is available from the authors. It is noted
that the clustering error defined in simulation can also measure the discrepancy of two clustering
results. The normalized clustering discrepancy values between any two of the seven approaches
are presented in Table 3. It is observed that the results from the proposed clustering are relatively
similar to those of Alt.1, Alt.2, and Alt.5, but quite different from the other three approaches.
The six alternatives generate results from relatively similar (e.g., Alt.3 and Alt.6) to significantly
different (e.g., Alt.2 and Alt.3). With practical data, it can be difficult to determine which clustering
is more accurate. The better simulation performance and sound interpretations can provide some
confidence to the proposed clustering.
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5 Discussion
In the analysis of NHIRD and other data alike, the prevalence of various diseases is of great
importance. Advancing from the literature, this study has taken a novel different strategy and
focused on the similarity in diseases’ prevalence trends under the functional clustering framework.
Another highlight is that a pan-disease approach has been taken, under which a total of 405 diseases
have been analyzed. This study is the first of its kind and, as described in Section 1, can have
important practical implications. The results can be informative to the Taiwan population and
health care/insurance system as well as other countries/regions and populations. A functional
clustering method has been proposed using the innovative penalized pursuit technique. It has been
shown to have competitive numerical performance and satisfactory statistical properties. It can
have broad applications in functional data analysis far beyond this study.
This study can be potentially extended in multiple directions. Disease prevalence depends on
multiple factors and varies across regions and populations. It can be of interest to conduct similar
analysis for other regions/populations. It is also noted that this can be very challenging with
the difficulty in obtaining data comparable to the NHIRD. The shared temporal trends of disease
prevalence can be caused by multiple factors. Some examples of plausible interpretations have been
provided. However, we defer to future research to more systematically and quantitatively quantify
the causes of similar trends. It is also of interest to apply the proposed method to other functional
data problems and conduct more comparisons.
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Appendix I: Statistical properties
In this study, we have been focused on methodological development and data analysis. To provide
more insight into the proposed method, we also briefly examine its statistical properties.
For the convenience of notation, we rewrite the objective function as
{βˆj : j = 1, . . . , N} = argmin

N∑
i=1
1
2
‖Yi −Bβi‖2 + λTK
∑
i<j
wij‖βi − βj‖
 . (7)
For this “new” objective function, we make the following assumptions:
(A1) T →∞,K →∞, K
T
→ 0, K( log(K))
3
T
→ 0.
(A2) λ
√
KTmax
i,j
{wij |βi 6= βj} = Op(1).
(A3) λ
√
TKmin
i,j
{wij |βi = βj} →P ∞.
It is noted that for lucidity, we have made assumptions directly on the wij ’s, which can be obtained
from the estimation properties of the underlying functions. For example, under Assumption A1
and certain regularity conditions, Corollary 2.1 of He & Shao (2010) can lead to ‖βˆolsi − βi‖ =
Op(
√
K/T ). In this case, λ = O(1/
√
TK) satisfies the assumptions.
Theorem 1 (Estimation consistency). ‖βˆi − βi‖ → Op(
√
K/T ), ∀i.
Proof. Let Ui ∈ RK , u = (U1, ..., UN )′ ∈ RNK andQ(β) =
∑N
i=1
1
2
‖Yi−Bβi‖2+λTK
∑
i<j≤N wij‖βi−
βj‖. We show that
lim
T
infP
(
inf
u∈RNK :‖Ui‖=∆
Q(β + U
√
K/
√
T ) > Q(β)
)
> 1− .
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Consider
Q(β + U
√
K/
√
T )−Q(β) = K
2T
N∑
i=1
u′i
(
B′B
)
ui −
N∑
i=1
u′i
(√
K√
T
B′(Yi −Bβi)
)
+ λTK
∑
i<j≤N
wij‖βi − βj − uij
√
K/
√
T‖ −
∑
i<j≤N
wij‖βi − βj‖
= .5K
N∑
i=1
u′i
(
B′B
T
)
ui −
N∑
i=1
u′i
(√
K√
T
B′(Yi −Bβi)
)
+ λTK
∑
i<j≤N
wij‖βi − βj − uij
√
K/
√
T‖ −
∑
i<j:C(i)6=C(j)
wij‖βi − βj‖
≥ .5K
N∑
i=1
u′i
(
B′B
T
)
ui −
N∑
i=1
u′i
(√
K√
T
B′(Yi −Bβi)
)
+ λKT
∑
i<j:C(i)6=C(j)
wij(‖βi − βj − uij
√
K/
√
T‖ − ‖βi − βj‖)
≥ .5K
N∑
i=1
u′i
(
B′B
T
)
ui − .5
N∑
i=1
u′i
(√
K√
T
B′(Yi −Bβi)
)
− λ
√
KTK
∑
i<j:C(i) 6=C(j)
wij‖uij‖.
Note that
B′B
T
converges to the identity matrix. For each i, the first term is quadratic in ui and
O(K); the second term is linear in ui with its coefficient being Op(K); and finally from assumption
A2, the last term is Op(K) and linear in ui. Thus, with a properly chosen ∆, the theorem can be
proved.
Theorem 2. (Clustering consistency) Consider any (i, j) with C(i) = C(j). Then P (Cˆ(i) =
Cˆ(j)) = P (βˆi = βˆj)→ 1.
Proof. Consider a cluster including curves y1, y2, that is, β1 = β2. Below we show that P (βˆ1 6=
βˆ2) = 0 by contradiction.
Suppose that βˆ1 6= βˆ2. Differentiating the objective function Q(β) with respect to β1 leads to
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the following normal equation:
B′(Y1 −Bβˆ1) + λTKw12‖βˆ1 − βˆ2‖
(βˆ1 − βˆ2) +
N∑
j=3
λTKw1j
‖βˆ1 − βˆj‖
(βˆ1 − βˆj) = 0,
B′(Y1 −Bβ1) +B′B(β1 − βˆ1) + λTKw12‖βˆ1 − βˆ2‖
(βˆ1 − βˆ2) +
N∑
j=3
λTKw1j
‖βˆ1 − βˆj‖
(βˆ1 − βˆj) = 0,
B′(Y1 −Bβ1)√
TK
+
B′B
T
√
T√
K
(β1 − βˆ1) + λ
√
TKw12
‖βˆ1 − βˆ2‖
(βˆ1 − βˆ2) +
N∑
j=3
λ
√
TKw1j
‖βˆ1 − βˆj‖
(βˆ1 − βˆj) = 0.
The first, second, and last terms are Op(1), and the third term dominates from Assumption A3,
leading to a contradiction. Thus, P (βˆi = βˆ2) = 1.
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Appendix II: Clustering results using the proposed approach
Table 4: Diseases in each cluster(proposed method)
Diseases
Cluster 1 Allergic purpura
Angiodysplasia of intestine (without mention of hemorrhage)
Bone cancer
Cancer of bladder
Cancer of other female genital organs, excluding uterus and ovary
Circadian rhythm sleep disorder
Diaphragmatic hernia
Disorders of phosphorus metabolism
Exostosis of jaw
Fluid overload
Folate-deficiency anemia
Glossodynia
Melanomas of skin
Ulceration of the lower GI tract
Cluster 2 Aneurysm of other specified artery
Decreased libido
Defibrination syndrome
Disorders of iron metabolism
Hyperchylomicronemia
Incisional hernia
Neoplasm of uncertain behavior of male genital organs
Polycythemia vera
Schizoid personality disorder
Cluster 3 Acquired hemolytic anemias
Autoimmune hemolytic anemias
Benign neoplasm of parathyroid gland
Carcinoma in situ of skin
Dissociative disorder
Lymphoid leukemia, chronic
Other disorders of testis
Cluster 4 Acquired coagulation factor deficiency
Appendicitis
Cancer of major salivary glands
Renal osteodystrophy
Reticulosarcoma
Cluster 5 Antisocial/borderline personality disorder
Aplastic anemia
28
Table 4: Diseases in each cluster(proposed method)
Diseases
Benign neoplasm of male genital organs
Cancer of liver and intrahepatic bile duct
Dementia with cerebral degenerations
Manlignant and unknown neoplasms of brain and nervous system
Myoclonus
Other disorders of lipoid metabolism
Paranoid disorders
Peripheral angiopathy in diseases classified elsewhere
Pneumonia due to fungus (mycoses)
Subarachnoid hemorrhage
Subdural hemorrhage
Tics and choreas
Cluster 6 Alzheimer’s disease
Benign neoplasm of respiratory and intrathoracic organs
Malignant neoplasm of bladder
Nephritis and nephropathy in diseases classified elsewhere
Thyroid cancer
Cluster 7 Atherosclerosis of aorta
Atherosclerosis of the extremities
Other benign neoplasm of uterus
Other deficiency anemia
Other disorders of prostate
Other inflammatory disorders of male genital organs
Paralysis/spasm of vocal cords or larynx
Proliferative glomerulonephritis
Cluster 8 Abdominal aortic aneurysm
Anomalies of jaw size/symmetry
Benign neoplasm of other female genital organs
Benign neoplasm of pituitary gland and craniopharyngeal duct (pouch)
Cancer of brain
Cancer of connective tissue
Cancer of lip
Cancer of oropharynx
Cancer of other female genital organs
Cancer of the gums
Cerebral aneurysm
Cerebral degeneration, unspecified
Cyst of the salivary gland
Degenerative disease of the spinal cord
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Table 4: Diseases in each cluster(proposed method)
Diseases
Disturbance of salivary secretion
Fibroadenosis of breast
Fibrosclerosis of breast
Gastroesophageal laceration-hemorrhage syndrome
Gram positive septicemia
Hypersomnia
Leukemia
Lymphoid leukemia, acute
Malignant neoplasm of gallbladder and extrahepatic bile ducts
Malignant neoplasm of kidney, except pelvis
Malignant neoplasm of small intestine, including duodenum
Multiple myeloma
Myeloid leukemia, acute
Neoplasm of uncertain behavior of skin
Nevus, non-neoplastic
Nodular lymphoma
Nonrheumatic pulmonary valve disorders
Other disorders of arteries and arterioles
Other disorders of carbohydrate transport and metabolism
Other disorders of purine and pyrimidine metabolism
Other hemoglobinopathies
Other vitamin B12 deficiency anemia
Posttraumatic stress disorder
Pulmonary embolism and infarction, acute
Raynaud’s syndrome
Spinocerebellar disease
Cluster 9 Acidosis
Acute posthemorrhagic anemia
Acute prostatitis
Benign neoplasm of brain, cranial nerves, meninges
Benign neoplasm of kidney and other urinary organs
Cancer of nasopharynx
Cancer of tongue
Cellulitis and abscess of trunk
Cyst of kidney, acquired
Delirium due to conditions classified elsewhere
Disease of tricuspid valve
Diseases of white blood cells
Hemangioma and lymphangioma, any site
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Table 4: Diseases in each cluster(proposed method)
Diseases
Hydrocephalus
Hypertensive heart and/or renal disease
Malignant neoplasm of uterus
Mitral valve stenosis and aortic valve stenosis
Non-Hodgkins lymphoma
Orchitis and epididymitis
Other specified disorders of plasma protein metabolism
Pancreatic cancer
Parasomnia
Prostatitis
Pseudomonal pneumonia
Secondary malignancy of brain/spine
Secondary malignant neoplasm
Sialoadenitis
Cluster 10 Arthralgia/ankylosis of temporomandibular joint
Benign neoplasm of lip, oral cavity, and pharynx
Benign neoplasm of ovary
Cancer of prostate
Cellulitis and abscess of foot, toe
Cerebral atherosclerosis
Dementias
Diseases of esophagus
Disorders of the autonomic nervous system
Essential tremor
Extrapyramidal disease and abnormal movement disorders
Glossitis
HIV infection, symptomatic
Hyperpotassemia
Intracerebral hemorrhage
Iron deficiency anemia secondary to blood loss (chronic)
Malignant neoplasm of rectum, rectosigmoid junction, and anus
Nasal polyps
Nonrheumatic aortic valve disorders
Other benign neoplasm of connective and other soft tissue
Renal failure NOS
Secondary malignancy of respiratory organs
Secondary malignant neoplasm of liver
Thrombocytopenia
Ulcer of esophagus
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Table 4: Diseases in each cluster(proposed method)
Diseases
Vascular dementia
Cluster 11 Acute renal failure
Acute, but ill-defined cerebrovascular disease
Agorophobia, social phobia, and panic disorder
Bipolar
Cervical intraepithelial neoplasia [CIN] [Cervical dysplasia]
Chronic prostatitis
Diseases of hard tissues of teeth
Gastrojejunal ulcer
Hepatitis NOS
Hyperglyceridemia
Hypertensive chronic kidney disease
Hyposmolality and/or hyponatremia
Iron deficiency anemias, unspecified or not due to blood loss
Myocardial infarction
Neoplasm of uncertain behavior
Other persistent mental disorders due to conditions classified elsewhere
Schizophrenia
Temporomandibular joint disorder, unspecified
Transient cerebral ischemia
Unspecified disorder of lipoid metabolism
Viral Enteritis
Cluster 12 Angina pectoris
Benign neoplasm of colon
Bronchopneumonia and lung abscess
Cellulitis and abscess of fingers/toes
Depression
Hemorrhage from gastrointestinal ulcer
Herpes zoster
Lump or mass in breast
Major depressive disorder
Nonrheumatic mitral valve disorders
Septicemia
Sleep disorders
Viral hepatitis C
Cluster 13 Chronic renal failure [CKD]
Diseases of the larynx and vocal cords
GERD
Hypercholesterolemia
32
Table 4: Diseases in each cluster(proposed method)
Diseases
Organic or persistent insomnia
Senile dementia
Uterine leiomyoma
Viral hepatitis B
Viral warts & HPV
Cluster 14 Cerebral artery occlusion, with cerebral infarction
Hypertensive heart disease
Stomatitis and mucositis (ulcerative)
Cluster 15 Acute glomerulonephritis, NOS
Aortic valve disease
ASCVD
Benign neoplasm of brain and other parts of nervous system
Cervical cancer and dysplasia
Encephalitis
Hereditary disturbances in tooth structure
Mitral valve disease
Other CNS infection and poliomyelitis
Peripheral vascular disease
Vesicoureteral reflux
Cluster 16 Arteritis NOS
Atherosclerosis
Inguinal hernia
Nephritis and nephropathy with pathological lesion
Viral pneumonia
Cluster 17 Chronic tonsillitis and adenoiditis
Diseases of pulp and periapical tissues
Cluster 18 Acute appendicitis
Acute febrile mucocutaneous lymph node syndrome (Kawasaki disease)
Acute pulmonary heart disease
Acute rheumatic heart disease
Appendiceal conditions
Atrophic gastritis
Cerebral ischemia
Diseases of the salivary glands
Disorders of calcium/phosphorus metabolism
Disorders of fluid, electrolyte, and acid-base balance
Encephalitis, non-infectious
Gout and other crystal arthropathies
Heart valve disorders
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Table 4: Diseases in each cluster(proposed method)
Diseases
Inflammatory diseases of prostate
Ischemic Heart Disease
Lipoma of skin and subcutaneous tissue
Neoplasm of uncertain behavior of breast
Other hereditary hemolytic anemias
Psychogenic and somatoform disorders
Purpura and other hemorrhagic conditions
Somatoform disorder
Thrombotic microangiopathy
Cluster 19 Benign neoplasm of unspecified sites
Schizophrenia and other psychotic disorders
Ulcerative colitis (chronic)
Cluster 20 Acute and chronic tonsillitis
Bacterial enteritis
Benign neoplasm of uterus
Cellulitis and abscess of oral soft tissues
Cysts of oral soft tissues
Disorders of lipoid metabolism
Duodenal ulcer
Loss of teeth or edentulism
Tuberculosis
Viral hepatitis
Cluster 21 Chronic hepatitis
Other local infections of skin and subcutaneous tissue
Cluster 22 Acute vascular insufficiency of intestine
Alkalosis
Aneurysm and dissection of heart
Aneurysm of iliac artery
Anterior horn cell disease
Azoospermia and oligospermia
Benign neoplasm of eye
Benign neoplasm of other endocrine glands and related structures
Breast cancer [male]
Cancer of bone and connective tissue
Cancer of other endocrine glands
Cancer of other lymphoid, histiocytic tissue
Cancer within the respiratory system
Celiac disease
Colorectal cancer
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Table 4: Diseases in each cluster(proposed method)
Diseases
Congenital coagulation defects
Dentofacial anomalies, including malocclusion
Disease of capillaries
Disorders of bilirubin excretion
Disorders of magnesium metabolism
Disorders of plasma protein metabolism
Diverticulum of esophagus, acquired
Hemoglobinuria
Hemorrhagic disorder due to intrinsic circulating anticoagulants
Hypersensitivity angiitis
Intestinal infection due to protozoa
Leprosy
Lesions of stomach and duodenum
Localized adiposity
Malignant neoplasm of head, face, and neck
Malignant neoplasm of other within the digestive organs and peritoneum
Malignant neoplasm of unspecified male genital organ
Megaloblastic anemia
Moyamoya disease
Nephritis and nephropathy without mention of glomerulonephritis
Non-autoimmune hemolytic anemias
Other specified diseases of the salivary glands
Paraproteinemia
Pernicious anemia
Phenylketonuria [PKU]
Pneumococcal pneumonia
Polyarteritis nodosa
Primary thrombocytopenia
Qualitative platelet defects
Renal sclerosis, NOS
Sickle cell anemia
Sideroblastic anemia
Small kidney
Specific nonpsychotic mental disorders due to brain damage
Spermatocele
Streptococcus infection
Stricture and stenosis of esophagus
Stricture of artery
Takayasus disease
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Table 4: Diseases in each cluster(proposed method)
Diseases
Thromboangiitis obliterans
Vascular disorders of kidney/hypertrophy
Vascular hamartomas and non-neoplastic nevi
Von willebrand’s disease
Cluster 23 Arterial embolism and thrombosis
Benign neoplasm of adrenal gland
Benign neoplasm of bone and articular cartilage
Benign neoplasm of thyroid glands
Chondrocalcinosis
Diseases of the jaws
Intestinal e.coli
Cluster 24 Infectious mononucleosis
Malignant neoplasm of ovary and other uterine adnexa
Multiple sclerosis
Primary pulmonary hypertension
Cluster 25 Acid-base balance disorder
Amyloidosis
Cancer of larynx, pharynx, nasal cavities
Complications of gastrostomy, colostomy and enterostomy
Disorders of penis
Intestinal malabsorption (non-celiac)
Lipoma
Malignant neoplasm, other
Mood disorders
Non-proliferative glomerulonephritis
Other cerebral degenerations
Other specified benign mammary dysplasias
Peripheral autonomic neuropathy
Personality disorders
Sexual and gender identity disorders
Tooth complications likely association with other diseases
Transient mental disorders due to conditions classified elsewhere
Umbilical hernia
Ventral hernia
Cluster 26 Cystic mastopathy
Overweight, obesity and other hyperalimentation
Cluster 27 Bacterial pneumonia
Gingival and periodontal diseases
Nephrotic syndrome without mention of glomerulonephritis
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Table 4: Diseases in each cluster(proposed method)
Diseases
Obesity
Ulceration of intestine
Cluster 28 Bacterial infection NOS
Balanoposthitis
Chronic obstructive asthma
Diseases of lips
Other acute and subacute forms of ischemic heart disease
Cluster 29 Chronic airway obstruction
Other chronic ischemic heart disease, unspecified
Cluster 30 Benign neoplasm of skin
Chronic obstructive asthma with exacerbation
Dysthymic disorder
Erectile dysfunction [ED]
Gout
Gouty arthropathy
Other diseases of the teeth and supporting structures
Regional enteritis
Cluster 31 Benign mammary dysplasias
Chronic pulmonary heart disease
Cluster 32 Coagulation defects
Disorders of esophageal motility
Cluster 33 Occlusion of cerebral arteries
Periapical abscess
Cluster 34 Cerebrovascular disease
Viral infection
Cluster 35 Disorders of function of stomach
Gastritis and duodenitis
Peptic ulcer (excl. esophageal)
Varicella infection
Cluster 36 Acute bronchitis and bronchiolitis
Acute gastritis
Acute pharyngitis
Acute sinusitis
Acute upper respiratory infections of multiple or unspecified sites
Anemia of chronic disease
Asthma
Asthma with exacerbation
Cancer, suspected or other
Cellulitis and abscess of arm/hand
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Table 4: Diseases in each cluster(proposed method)
Diseases
Dyspepsia and other specified disorders of function of stomach
Essential hypertension
Gastritis and duodenitis, NOS
Gingivitis
Mixed hyperlipidemia
Noninfectious gastroenteritis
Oral aphthae
Other anemias
Other upper respiratory disease
Periodontitis (acute or chronic)
Reflux esophagitis
Superficial cellulitis and abscess
Dental caries
Atopic/contact dermatitis due to other or unspecified
Functional digestive disorders
Type 2 diabetes
Influenza
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Appendix III: Clustering results using the alternatives
Figure 4: Clustering results using Alt.1.
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Figure 5: Clustering results using Alt.2.
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Figure 6: Clustering results using Alt.3.
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Figure 7: Clustering results using Alt.4.
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Figure 8: Clustering results using Alt.5.
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Figure 9: Clustering results using Alt.6.
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